共 84 条
[1]
Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34
[2]
Miller KD(2017)Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 35 3484-3515
[3]
Jemal A(2005)Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 339-346
[4]
Hanna N(2014)U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations Oncologist 19 774-779
[5]
Johnson D(2007)Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 169-181
[6]
Temin S(2016)The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis Oncotarget 7 78985-78993
[7]
Shigematsu H(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[8]
Lin L(2011)Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay Clin Cancer Res 17 1169-1180
[9]
Takahashi T(2013)Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors Lung Cancer 82 294-298
[10]
Khozin S(2014)Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients Lung Cancer 85 19-24